AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23059357
Drug: Standard two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard two 0.25 mL doses given four weeks apart
Trial: 20147716
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (10 mg/kg body weight, single infusion)
Trial: 20147716
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B deoxycholate (1 mg/kg, 15 infusions every other day during a 29-day hospitalization)
Trial: 17980416
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg budesonide + 9 microg formoterol (twice daily, 100 microg per dose; n = 20)
Trial: 17980416
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg budesonide + 5 or 10 mg montelukast (once daily at bedtime; n = 20)
Trial: 17980416
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 10 mg montelukast (n = 20)
Trial: 16751933
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg/day)
Trial: 16751933
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UH) (5,000 IU t.i.d.)
Trial: 14521593
Drug: Ximelagatran 24
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 24 mg bid
Trial: 14521593
Drug: Enoxaparin 30
RxNorm normalized name: ENOXAPARIN 30MG/0.3ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 30 mg bid
Trial: 10413638
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy including bedrest, anti-ischaemic medications, aspirin, and heparin.
Trial: 8673551
Drug: Interest in
RxNorm normalized name: CATH,INTERMIT,14FR MENTOR #3814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interest in participating in HIV preventive vaccine trials
Trial: 8673551
Drug: Perceived peer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived peer willingness to enroll in vaccine trials
Trial: 8673551
Drug: Optimism about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimism about success in vaccine development
Trial: 8673551
Drug: Vaccine‐induced seroconversion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine‐induced seroconversion
Trial: 1765571
Drug: Triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25 or 0.50 mg)
Trial: 28884296
Drug: Bisphosphonate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate therapy (pamidronate and zoledronic acid, mean 2.95 infusions per patient)
Trial: 21178077
Drug: Cereal L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal L fortified with electrolytic iron (54.5 mg iron/100 g cereal)
Trial: 21178077
Drug: Cereal M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal M fortified with ferrous fumarate (52.2 mg Fe/100 g)
Trial: 16996833
Drug: Half-dose TNK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose TNK with abciximab and reduced-dose UFH
Trial: 12679443
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at a dosage of 0.067 mg/kg.d until attainment of adult height
Trial: 11782853
Drug: Metoprolol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol IR 50 mg 3 times daily
Trial: 12818732
Drug: Metoprolol CR/XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/XL 100 mg once daily
Trial: 24247812
Drug: Metoprolol CR/XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/XL 200 mg once daily
Trial: 9386657
Drug: Indomethacin and
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin and Ibuprofen (both treatments)
Trial: 7904762
Drug: Fluphenazine (FPZ)
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine (FPZ) 20 mg/day
Trial: 7904762
Drug: Fluphenazine (FPZ)
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine (FPZ) 80 mg/day
Trial: 7904762
Drug: Fluphenazine (FPZ)
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine (FPZ) 20 mg/day (open phase)
Trial: 29148929
Drug: Alcohol-Wise (version
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-Wise (version 4.0, 3rd Millennium Classrooms) administered prior to first semester
Trial: 21346067
Drug: MRrhTSH 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRrhTSH 0.01 mg (group B, n = 30)
Trial: 21346067
Drug: MRrhTSH 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRrhTSH 0.03 mg (group C, n = 33)
Trial: 14636819
Drug: morphine 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 18 mg/70 kg intramuscular
Trial: 14636819
Drug: morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 10 mg/70 kg intravenous
Trial: 14636819
Drug: hydromorphone 2
RxNorm normalized name: HYDROmorphone 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydromorphone 2 mg/70 kg intravenous
Trial: 8840306
Drug: 0.5 micrograms/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 micrograms/day oral calcitriol (calcitriol group, n = 8)
Trial: 8840306
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day calcium carbonate (CaCO3 group, n = 10)
Trial: 1729619
Drug: Topical 0.1
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1 percent tretinoin
Trial: 3885699
Drug: Tiapamil (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil (1.5 mg/kg intravenous bolus followed by 50 micrograms/kg/min infusion for 3 hours)
Trial: 20018492
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of piperacillin (16g/day)
Trial: 20018492
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus dosing of piperacillin (4g every 6h)
Trial: 16622039
Drug: 0.6 mg/h
RxNorm normalized name: nitroglycerin 0.6 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/h GTN for 1 week (n=17)
Trial: 16622039
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n=11)
Trial: 6539224
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg codeine phosphate
Trial: 6539224
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg dextromethorphan hydrobromide
Trial: 8830977
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dextromethorphan hydrobromide
Trial: 23475835
Drug: Contact lens
RxNorm normalized name: contact lens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact lens (CL) treatment
Trial: 18972725
Drug: Three-combination needling
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-combination needling method (acupuncture, acupoint-injection, fire-needle therapy)
Trial: 18972725
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and acupoint-injection (control group)
Trial: 12642637
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Trial: 10713746
Drug: Borage oil
RxNorm normalized name: Borage oil
DrugBank: Borage oil (DB11238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Borage oil supplementation (230 or 460 mg gamma‐linolenic acid per day for one week)
Trial: 1314965
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (1500 a PPT-Units/d Mono-Embolex NM)
Trial: 9531030
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (5000 IU t.i.d.)
Trial: 23913972
Drug: Asoprisnil (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asoprisnil (a progesterone receptor modulator)
Trial: 10101617
Drug: Exchanging drugs
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Exchanging drugs or money for sex
Trial: 7485711
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (4 mg/kg/day for three days with mefloquine 25 mg/kg on the second day)
Trial: 7485711
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine (20 mg of salt/kg initially then 10 mg/kg every 8 hr, followed by mefloquine 25 mg/kg)
Trial: 31028737
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration of 4% articaine 1.8 mL
Trial: 31028737
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration of 4% articaine 1.8 mL plus lingual injection of normal saline 0.4 mL
Trial: 22018594
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg somatuline® (lanreotide) administered by a single subcutaneous injection for 2 weeks (Group B)
Trial: 22018594
Drug: Paclitaxel 190
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 190 mg/m2 + carboplatin AUC=5.5 for up to 6 cycles (Group A, control group)
Trial: 22018594
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg somatuline® autogel for 4 weeks (Group C)
Trial: 17428109
Drug: Exenatide (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (subcutaneous, twice daily)
Trial: 15522938
Drug: Cinacalcet (30-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (30-50 mg twice daily)
Trial: 7486180
Drug: ondansetron (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (0.1 mg/kg)
Trial: 31106492
Drug: Transitioning to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transitioning to very low nicotine content cigarettes plus nicotine patch
Trial: 31106492
Drug: Reducing daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reducing daily cigarette consumption plus nicotine patch
Trial: 21419770
Drug: peginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2b (0.5 μg/kg/week)
Trial: 19046169
Drug: Lactobacillus-containing vaginal
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus-containing vaginal tablets
Trial: 17429915
Drug: rhEPO (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO (250 IU/kg three times weekly, total of 15 times starting on day of life 5)
Trial: 10867388
Drug: Integral valuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integral valuation of treatment
Trial: 6442856
Drug: Semi-elemental diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-elemental diet (SED) with an osmolarity of 302 milliosmol per liter, low lactose content, and high lactalbumin hydrolysate (1 g/100 ml)
Trial: 26604159
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) for 12 hours (loading dose 4g IV, maintenance 1g/hour)
Trial: 26604159
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) for 24 hours (loading dose 4g IV, maintenance 1g/hour)
Trial: 25740794
Drug: valACV 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valACV 500 mg twice daily for 12 weeks
Trial: 18619359
Drug: Bailing capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bailing capsule and medical gymnastics
Trial: 18619359
Drug: Routine western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine western medicine (Control)
Trial: 12568831
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of E2
Trial: 12568831
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of E2 + 5 mg of medroxyprogesterone acetate (MPA)
Trial: 8854286
Drug: Theophylline Lavipharm
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline Lavipharm (200 mg or 300 mg)
Trial: 8854286
Drug: Theodur (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theodur (200 mg or 300 mg)
Trial: 1607899
Drug: Weekly non-response
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly non-response
Trial: 6092012
Drug: cefotaxime 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefotaxime 3 x 2 g
Trial: 6092012
Drug: lamoxactam 3
RxNorm normalized name: Lamoxactam
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lamoxactam 3 x 2 g
Trial: 6092012
Drug: cefmenoxime 3
RxNorm normalized name: cefmenoxime
DrugBank: Cefmenoxime (DB00267)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefmenoxime 3 x 1 g
Trial: 6092012
Drug: mezlocillin 3
RxNorm normalized name: mezlocillin 3 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mezlocillin 3 x 5 g
Trial: 6092012
Drug: piperacillin 3
RxNorm normalized name: piperacillin 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperacillin 3 x 4 g
Trial: 31121926
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplements (ONS) - 2 packs daily for 8 weeks
Trial: 31121926
Drug: Non-Oral Nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Oral Nutritional Supplements (non-ONS)
Trial: 20137063
Drug: Naprapathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprapathic manual therapy (spinal manipulation/mobilization, massage, and stretching)
Trial: 15640478
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (approximately 670 mg/d)
Trial: 12360174
Drug: Intravenous monteplase
RxNorm normalized name: Monteplase
DrugBank: Monteplase (DB12726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous monteplase pretreatment before coronary angioplasty (Group II)
Trial: 9010610
Drug: sustained-release ibuprofen
RxNorm normalized name: ibuprofen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release ibuprofen (1600 mg daily)
Trial: 9010610
Drug: sustained-release diclofenac
RxNorm normalized name: diclofenac Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release diclofenac sodium (100 mg daily)
Trial: 3883375
Drug: Epinephrine solution
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine solution instillation into the breast parenchyma
Trial: 20735834
Drug: Thymostimulin 75
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin 75 mg s.c. 5x/week
Trial: 18242365
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate sodium (PPS) 300 mg/day for 32 weeks
Trial: 10411795
Drug: Clomiphene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene (50 mg days 5 to 9)
Trial: 7756105
Drug: Amantadine HCl
RxNorm normalized name: amantadine HCl
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine HCl (3 mg kg‐1)
Trial: 7014656
Drug: Propiram fumarate
RxNorm normalized name: fumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiram fumarate (50 mg)
Trial: 31204198
Drug: Single shot
RxNorm normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single shot of intravenous TXA 10 mg/kg
Trial: 27989852
Drug: 30mg morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg morphine
Trial: 18723314
Drug: Gemcitabine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine + Tipifarnib (G+t)
Trial: 18723314
Drug: Gemcitabine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine + Placebo (G+p)
Trial: 16702498
Drug: Tazarotene gel
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene gel plus placebo capsules
Trial: 16702498
Drug: Minocycline capsules
RxNorm normalized name: minocycline Oral Capsule
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline capsules plus vehicle gel
Trial: 16702498
Drug: Tazarotene gel
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene gel plus minocycline capsules
Trial: 15611422
Drug: Oral alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alitretinoin 10 mg/d
Trial: 15611422
Drug: Oral alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alitretinoin 20 mg/d
Trial: 15611422
Drug: Oral alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alitretinoin 40 mg/d
Trial: 11697833
Drug: Early hyperfractionated
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early hyperfractionated thoracic radiation therapy (HTRT) concurrently with the first cycle of chemotherapy (Group A)
Trial: 11697833
Drug: Late hyperfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late hyperfractionated thoracic radiation therapy (HTRT) concurrently with the fourth cycle of chemotherapy (Group B)
Trial: 9397246
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 or 10 mg)
Trial: 9397246
Drug: Diltiazem (180,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180, 240, or 360 mg)
Trial: 19371522
Drug: Intravenous prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prochlorperazine (10 mg)
Trial: 7978566
Drug: Rectal prochlorperazine
RxNorm normalized name: prochlorperazine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal prochlorperazine (25 mg)
Trial: 7978566
Drug: Intravenous prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prochlorperazine
Trial: 7978566
Drug: Rectal prochlorperazine
RxNorm normalized name: prochlorperazine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal prochlorperazine
Trial: 2498820
Drug: Autoinflation (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autoinflation (3 times daily for 2 weeks)
Trial: 31434782
Drug: SBRT monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBRT monotherapy (40 Gy in five fractions given on alternating days)
Trial: 31434782
Drug: Virtual high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual high-dose rate boost (HDRB) (20 Gy in two fractions followed by 36 Gy in 12 fractions)
Trial: 28158982
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment (50 micrograms daily, titrated according to TSH level)
Trial: 24800335
Drug: Clean Intermittent
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clean Intermittent Self Catheterisation (CISC) performed by inserting a Classic Neleton Catheter (No. 16 or 18) twice a day for 1 week, then once a day for another 4 weeks and then once weekly continued for one year.
Trial: 18052950
Drug: Topiramate 100
RxNorm normalized name: topiramate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 100 mg per day
Trial: 15254052
Drug: Irinotecan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 100 mg/m² weekly for 4 weeks followed by a 2-week rest (weekly arm)
Trial: 15254052
Drug: Irinotecan 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 240 mg/m² every 3 weeks (every‐3‐weeks arm)
Trial: 28960663
Drug: High-dose transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose transdermal nicotine (90 mg/day)
Trial: 25913046
Drug: Hypotonic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic solution (Na 30 mEq/L NaCl or 0.18%)
Trial: 25913046
Drug: Isotonic solution
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic solution (Na 150 mEq/L or 0.9% NaCl)